NRSN
Neurosense Therapeutics LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$29.60M
P/E Ratio
—
EPS
$-0.44
Beta
1.58
52W High
$2.60
52W Low
$0.63
50-Day MA
$0.78
200-Day MA
$0.98
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Neurosense Therapeutics Ltd
Neurosense Therapeutics Ltd (NRSN) is a forward-thinking clinical-stage biotechnology firm dedicated to revolutionizing treatments for neurodegenerative diseases, with a primary emphasis on Parkinson's disease. Utilizing its proprietary development platform, the company is advancing a promising pipeline of innovative therapeutic candidates that are currently under pivotal clinical trials, aimed at addressing critical unmet medical needs within the neurology domain. Backed by an experienced management team and strategic partnerships, Neurosense is positioned to deliver groundbreaking therapies that enhance patient outcomes and solidify its competitive standing in the biopharmaceutical industry.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-11.07M |
| Operating Margin | 0.00% |
| Return on Equity | -2175.00% |
| Return on Assets | -247.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.05 |
| Price-to-Book | 2.64 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $36.10M |
| Float | $26.03M |
| % Insiders | 32.30% |
| % Institutions | 1.07% |
Historical Volatility
HV 10-Day
71.09%
HV 20-Day
72.90%
HV 30-Day
62.78%
HV 60-Day
63.11%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($6.50 target)
4
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026